Alcon this week announced it is acquiring Belkin Vision for up to $385 million.
The deal includes an upfront consideration of $81 million, a cash payment of approximately $65 million, and the potential for up to $385 million in payments contingent upon rigorous sales-based milestones.
Alcon is acquiring Belkin Vision’s Direct Selective Laser Trabeculoplasty (DSLT) technology to expand its glaucoma portfolio with a first-line therapy. Currently, the company offers implants such as Hydrus Microstent and pharmaceutical drops.
“As a therapy with significant advantages for the patient and practice, we believe our newly acquired DSLT technology is uniquely positioned to accelerate the evolution toward first-line use of SLT in the glaucoma treatment paradigm,” said Sean Clark, president of the Global Surgical Franchise at Alcon. “We look forward to broadening access to this exciting technology in the future as we continue to address solutions for unmet needs in glaucoma.”
The DSLT technology has been approved by the EU and the U.K. It is indicated for selective laser trabeculoplasty. Belkin’s system received FDA 510(k) clearance but is not yet available in the U.S.
Alcon plans to continue supplying the DSLT in the EU and the U.K. and to make it available to doctors in the U.S. by the end of this year.
